Towards Optimal Treatment for High Risk Prostate Cancer
Recruiting now · Not applicable
Conditions studied: High Risk Prostate Carcinoma
In brief
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments. * patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation) * the tumor will get a higher dose * androgen deprivation therapy will be reduced as much al possible preventing side effects Researchers will compare oncological outcome and toxicity.
Key facts
- Study ID
- NCT06204341
- Run by
- Haaglanden Medical Centre
- People needed
- 207
- Starts
- 2024-01-02
- Expected to finish
- 2032-12-18
- Last updated by the study team
- 2024-09-19
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Men (aged ≥18 years of age) diagnosed within 6 months before inclusion with high risk prostate cancer:
- T3 based on digital rectal examination AND/OR
- Grade >= 4 AND/OR
- PSA >=20 ug/L
- Indication for elective lymph node irradiation (based on current clinical guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes)
You may not qualify if…
- Prior pelvic radiotherapy
- TransUrethral Resection of the Prostate (TURP) < 3 months ago
- Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU, cryotherapy, etc)
- contraindications to MRI
- no visible lesion on MRI in prostate for boost
- no PSMA-PET scan
- inflammatory bowel disease
- metastatic disease (M1)
- PSA >50
- unsuitable for SBRT or WPRT
- medical history of cancer other than basal cell carcinoma of the skin
Where it is running
- Haaglanden Medical Centre — Leidschendam, South Holland, Netherlands (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.